Document is current
Any future updates will be listed below
-
Authors
Cano, Florencia
Bravo-Blas, Alberto
Colombe, Mathilde
Cerrato, Chiara
Venigalla, Ram Kumar Chowdary
Preham, Olivier
Burns, Ellie
Mortimer, Paige
Choudhry, Aalia
Slipek, Nicholas
Johnson, Matthew J.
Webber, Beau R.
Moriarity, Branden S. https://orcid.org/0000-0002-3031-3767
Lou, Emil https://orcid.org/0000-0002-1607-1386
Choudhry, Modassir
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
Henley, Tom https://orcid.org/0009-0007-5060-7600
- License Information
-
More Information
Article History
Received: 25 June 2025
Accepted: 13 January 2026
First Online: 24 January 2026
Competing interests
: C.A.K. is an inventor on patents related to TCR discovery and public neoantigen-reactive TCRs unrelated to the present manuscript that have been licensed to Intima Biosciences and is recipient of licensing revenue shared according to MSKCC institutional policies. C.A.K. has consulted for or is on the scientific advisory boards for Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Chronara Biosciences, Decheng Capital, G1 Therapeutics, Klus Pharma, Merck, Obsidian Therapeutics, PACT Pharma, Roche/Genentech, Royalty Pharma, Stereo Biotherapeutics, and T-knife. C.A.K. is a scientific co-founder and equity holder in Affini-T Therapeutics. The other authors declare no competing interests.
